ASA: Rapid Endovascular Therapy Beneficial in Ischemic Stroke

Share this content:
ASA: Rapid Endovascular Therapy Beneficial in Ischemic Stroke
ASA: Rapid Endovascular Therapy Beneficial in Ischemic Stroke

WEDNESDAY, Feb. 11, 2015 (HealthDay News) -- For patients with ischemic stroke, rapid endovascular therapy is associated with improved outcomes, according to two studies published online Feb. 11 in the New England Journal of Medicine. The research was published to coincide with the American Stroke Association's International Stroke Conference, held from Feb. 11 to 13 in Nashville, Tenn.

Bruce C.V. Campbell, M.B.B.S., Ph.D., from the Royal Melbourne Hospital in Australia, and colleagues randomized patients with ischemic stroke who were receiving alteplase less than 4.5 hours after stroke onset to undergo endovascular thrombectomy with the Solitaire Flow Restoration stent retriever or to continue receiving alteplase alone. The trial was stopped early due to efficacy after 70 patients had undergone randomization. The researchers found that the there was a greater percentage of ischemic territory that had undergone reperfusion at 24 hours in the endovascular-therapy group than in the alteplase-only group.

Mayank Goyal, M.D., from the University of Calgary in Canada, and colleagues randomized patients with acute ischemic stroke with a small infarct core, a proximal intracranial arterial occlusion, and moderate-to-good collateral circulation to receive standard care (118 patients) or standard care plus endovascular treatment with available thrombectomy devices (intervention; 120 patients). The trial was stopped early due to efficacy. The researchers found that the rate of functional independence was increased in the intervention versus the control group (53.0 versus 29.3 percent; P < 0.001).

"Among patients with acute ischemic stroke with a proximal vessel occlusion, a small infarct core, and moderate-to-good collateral circulation, rapid endovascular treatment improved functional outcomes and reduced mortality," Goyal and colleagues write.

The Goyal study was partially funded by Covidien, the manufacturer of the Solitaire stent used in both studies.

Abstract - Campbell
Full Text
Abstract - Goyal
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »